Heat shock 70 kDa protein fusion protein (HSP70 fusion protein)

Heat shock 70 kDa protein (HSP70) fusion proteins represent a therapeutic modality rather than a traditional molecular target. In this approach, HSP70, a molecular chaperone, is genetically or chemically fused to a specific antigen, such as a viral protein or a tumor-associated antigen (Srivastava, 2002, PubMed: 12191204). The primary biological function of HSP70 in this context is to act as a potent immunological adjuvant that facilitates the uptake of the fused antigen by professional antigen-presenting cells (APCs), such as dendritic cells. This process is often mediated by receptors like CD91 (low-density lipoprotein receptor-related protein 1), which recognize HSP70 and trigger receptor-mediated endocytosis (Basu et al., 2001, PubMed: 11175804). Once internalized, the antigen is processed and cross-presented on MHC class I and II molecules, leading to the robust activation of CD8+ cytotoxic T lymphocytes and CD4+ helper T cells. This mechanism is particularly relevant in the treatment of cancers and chronic viral infections, where a strong cellular immune response is required to eliminate diseased cells (Chu et al., 2000, PubMed: 10881581). Drugs utilizing this platform, such as those targeting Human Papillomavirus (HPV) antigens, aim to redirect the immune system to recognize and destroy infected or malignant tissues. Consequently, while HSP70 itself is a well-characterized protein (UniProt: P0DMV8), the "No direct molecular target" designation often found in clinical databases reflects that the therapeutic effect is achieved through broad immune system modulation rather than the inhibition or activation of a single endogenous signaling protein.

Other names

HSP70-antigen fusionHsp70-peptide fusionHeat shock protein 70-based vaccineHSP70-E7 fusion protein

HSP70 fusion proteins function by utilizing the chaperone properties of HSP70 to deliver fused antigens to antigen-presenting cells (APCs) via receptor-mediated endocytosis, typically through the CD91 receptor. This process enhances the cross-presentation of the fused antigens on MHC class I and II molecules, thereby stimulating a potent, antigen-specific cytotoxic T-lymphocyte (CTL) and helper T-cell response against cells expressing the target antigen.